Review Article | Published:

Major lung complications of systemic sclerosis

Nature Reviews Rheumatologyvolume 14pages511527 (2018) | Download Citation

Abstract

Systemic sclerosis (SSc) is associated with high mortality owing to internal organ complications, and lung disease is the leading cause of SSc-associated death. The most notable lung complications in SSc are fibrosis and pulmonary arterial hypertension (PAH). A major challenge for the management of lung disease in SSc is detecting those patients with severe pathology and those patients who are likely to benefit from available treatments. In the past few years, strategies for managing lung fibrosis and pulmonary hypertension, including PAH, have greatly progressed. For lung fibrosis, the tools to assess risk of progression and severity of the disease have been refined. Clinical trial results support the use of immunosuppression, including high-intensity regimens with autologous stem cell transplantation. New trials are underway to test other potential therapies including treatments that are approved for use in idiopathic lung fibrosis. For PAH, identifying individuals at high risk of disease development is critical. In addition, individuals who have borderline elevation of pulmonary arterial pressure need to be appropriately managed and followed up. Many approved drugs targeting PAH are now available, and results from large-scale clinical trials provide robust evidence that various treatments for SSc-associated PAH are associated with good long-term outcomes.

Key points

  • Lung complications are frequent in systemic sclerosis (SSc) and include lung fibrosis and pulmonary hypertension, which have a substantial effect on disease outcomes and are major causes of SSc-related death.

  • Systematic evaluation of patients ensures that diagnosis of lung fibrosis and pulmonary hypertension is timely and permits treatment at the earliest possible stage.

  • Multiple licensed therapies exist for pulmonary arterial hypertension, and use of these agents alone and in combination has improved outcomes and survival in event-driven trials.

  • There are no approved therapies for lung fibrosis, but treatment with immunosuppression seems beneficial in clinical trials and is recommended for appropriate patients with severe or progressive lung fibrosis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Poudel, D. R., Jayakumar, D., Danve, A., Sehra, S. T. & Derk, C. T. Determinants of mortality in systemic sclerosis: a focused review. Rheumatol. Int. https://doi.org/10.1007/s00296-017-3826-y (2017).

  2. 2.

    Hao, Y. et al. Early mortality in a multinational systemic sclerosis inception cohort. Athritis Rheumatol. 69, 1067–1077 (2017).

  3. 3.

    Elhai, M. et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 76, 1897–1905 (2017).

  4. 4.

    Rubio-Rivas, M. Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clin. Exp. Rheumatol. 35 (Suppl. 106), 40–47 (2017).

  5. 5.

    Denton, C. P. & Khanna, D. Systemic sclerosis. Lancet 390, 1685–1699 (2017).

  6. 6.

    Denton, C. P. Systemic sclerosis: from pathogenesis to targeted therapy. Clin. Exp. Rheumatol. 33, S3–7 (2015).

  7. 7.

    Silver, R. M. & Feghali-Bostwick, C. A. Editorial: molecular insights into systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 66, 485–487 (2014) (2014).

  8. 8.

    Hsu, E. et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 63, 783–794 (2011).

  9. 9.

    Lindahl, G. E. et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir. Res. 14, 80 (2013).

  10. 10.

    Goh, N. S. et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 56, 2005–2012 (2007).

  11. 11.

    Shi-Wen, X. et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum. 40, 1237–1244 (1997).

  12. 12.

    Shi-wen, X. & Kennedy, L. et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum. 56, 4189–4194 (2007).

  13. 13.

    Shi-Wen, X. et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol. 26, 625–632 (2007).

  14. 14.

    Liu, F. et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L344–357 (2015).

  15. 15.

    Mendoza, F. A., Piera-Velazquez, S., Farber, J. L., Feghali-Bostwick, C. & Jiménez, S. A. Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 68, 210–217 (2016).

  16. 16.

    Gilbane, A. J., Denton, C. P. & Holmes, A. M. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res. Ther. 15, 215 (2013).

  17. 17.

    De Lauretis, A. et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J. Rheumatol. 40, 435–446 (2013).

  18. 18.

    van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433–443 (2014).

  19. 19.

    Wu, M. et al. CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts. Arthritis Rheumatol. 69, 1871–1878 (2017).

  20. 20.

    Denton, C. P. et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J. Biol. Chem. 278, 25109–25119 (2013).

  21. 21.

    Goh, N. S. et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur. Respir. J. 38, 184–190 (2011).

  22. 22.

    Richardson, C. et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin. Arthritis Rheum. 46, 109–114 (2016).

  23. 23.

    Christmann, R. B., Wells, A. U., Capelozzi, V. L. & Silver, R. M. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin. Arthritis Rheum. 40, 241–249 (2010).

  24. 24.

    Henderson, N. C. et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617–1624 (2013).

  25. 25.

    Sonnylal, S. et al. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 56, 334–344 (2007).

  26. 26.

    Hoyles, R. K. et al. Fibroblast-specific perturbation of transforming growth factor β signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 58, 1175–1188 (2008).

  27. 27.

    Hoyles, R. K. et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am. J. Respir. Crit. Care Med. 183, 249–261 (2011).

  28. 28.

    Watanabe, T. et al. Optimization of a murine and human tissue model to recapitulate dermal and pulmonary features of systemic sclerosis. PLOS One 12, e0179917 (2017).

  29. 29.

    Sun, H. et al. Netrin-1 regulates fibrocyte accumulation in the decellularized fibrotic sclerodermatous lung microenvironment and in bleomycin-induced pulmonary fibrosis. Arthritis Rheumatol. 68, 1251–1261 (2016).

  30. 30.

    Tourkina, E. et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogen. Tissue Repair. 4, 15 (2011).

  31. 31.

    Misharin, A. V. et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J. Exp. Med. 214, 2387–2404 (2017).

  32. 32.

    Martyanov, V. et al. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLOS One 12, e0187580 (2017).

  33. 33.

    Assassi, S. et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum. 65, 2917–2927 (2013).

  34. 34.

    Taroni, J. N. et al. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 9, 27 (2017).

  35. 35.

    Mayes, M. D. et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am. J. Hum. Genet. 94, 47–61 (2014).

  36. 36.

    Stock, C. J. et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68, 436–441 (2013).

  37. 37.

    Bossini-Castillo, L. et al. A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res. Ther. 14, R85 (2012).

  38. 38.

    Lagan, A. L. et al. Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. Rheumatology 44, 197–201 (2005).

  39. 39.

    Chu, H. et al. Sirtuin1 protects against systemic sclerosis-related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes. Am. J. Respir. Cell. Mol. Biol. 58, 28–39 (2018).

  40. 40.

    Fonseca, C. et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N. Engl. J. Med. 357, 1210–1220 (2007).

  41. 41.

    Kawaguchi, Y. et al. Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. Ann. Rheum. Dis. 68, 1921–1924 (2001).

  42. 42.

    Rueda, B. et al. A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann. Rheum. Dis. 68, 1618–1620 (2009).

  43. 43.

    Zhang, X., Nie, S., Si, X., Luo, Y. & Tang, W. Association between the CTGF -945C/G polymorphism and systemic sclerosis: a meta-analysis. Gene 509, 1–6 (2012).

  44. 44.

    Zhao, W. et al. The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms. Rheumatol Int. 37, 1303–1310 (2017).

  45. 45.

    Christmann, R. B. et al. miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res. Ther. 18, 155 (2016).

  46. 46.

    Tang, X. et al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am. J. Pathol. 183, 470–479 (2013).

  47. 47.

    Mehta, H. et al. Early-life antibiotic exposure causes intestinal dysbiosis and exacerbates skin and lung pathology in experimental systemic sclerosis. J. Invest. Dermatol. 137, 2316–2325 (2017).

  48. 48.

    Avouac, J. et al. Role of stromelysin 2 (matrix metalloproteinase 10) as a novel mediator of vascular remodeling underlying pulmonary hypertension associated with systemic sclerosis. Arthritis Rheumatol. 69, 2209–2221 (2017).

  49. 49.

    Hemnes, A. R. & Humbert, M. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. Eur. Respir. Rev. 26, 170093 (2017).

  50. 50.

    Davies, R. J. et al. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am. J. Physiol. Lung Cell. Mol. Physiol. 302, L604–615 (2012).

  51. 51.

    Gilbane, A. J. et al. Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis. Am. J. Respir. Crit. Care Med. 191, 665–677 (2015).

  52. 52.

    Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 66, 1625–1635 (2014).

  53. 53.

    Cheong, F. Y., Gower, A. C. & Farber, H. W. Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Semin. Arthritis Rheum. 46, 465–472 (2017).

  54. 54.

    Good, R. B. et al. Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension. Am. J. Pathol. 185, 1850–1858 (2015).

  55. 55.

    Korman, B. D. et al. Brief report: association of elevated adipsin levels with pulmonary arterial hypertension in systemic sclerosis. Arthritis Rheumatol. 69, 2062–2068 (2017).

  56. 56.

    Bossini-Castillo, L. et al. An MIF Promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis. J. Rheumatol. 44, 1453–1457 (2017).

  57. 57.

    Garcia-Rivas, G., Jerjes-Sánchez, C., Rodriguez, D., Garcia-Pelaez, J. & Trevino, V. A systematic review of genetic mutations in pulmonary arterial hypertension. BMC Med. Genet. 18, 82 (2017).

  58. 58.

    Schwaiger, J. P. et al. Optical coherence tomography evaluation of pulmonary arterial vasculopathy in systemic sclerosis. Sci. Rep. 7, 43304 (2017).

  59. 59.

    Olsson, K. M. 1 & Delcroix, M. et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 129, 57–65 (2014).

  60. 60.

    Daraban, A. M. et al. Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension in systemic sclerosis. Case presentation and review of the literature. Rom. J. Intern. Med. 53, 175–183 (2015).

  61. 61.

    Connolly, M. J. et al. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. Rheumatology 56, 2197–2203 (2017).

  62. 62.

    Nihtyanova, S. I. et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 103, 109–115 (2010).

  63. 63.

    Denton, C. P. et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 55, 1906–1910 (2016).

  64. 64.

    Guler, S. A. et al. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. Respir. Med. 129, 1–7 (2017).

  65. 65.

    Lumetti, F. et al. Quality of life and functional disability in patients with interstitial lung disease related to systemic sclerosis. Acta Biomed. 86, 142–148 (2015).

  66. 66.

    Vacca, A. et al. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology 53, 1172–1177 (2014).

  67. 67.

    Wells, A. U. & Denton, C. P. Interstitial lung disease in connective tissue disease—mechanisms and management. Nat. Rev. Rheumatol. 10, 728–739 (2014).

  68. 68.

    Desai, S. R. et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 232, 560–567 (2004).

  69. 69.

    Suliman, Y. A. et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol. 67, 3256–3261 (2015).

  70. 70.

    Buch, M. H. et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann. Rheum. Dis. 66, 169–173 (2007).

  71. 71.

    Khanna, D. et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum. 65, 3194–3201 (2015).

  72. 72.

    Morrisroe, K. et al. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res. Ther. 19, 122 (2017).

  73. 73.

    Hachulla, E. et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 60, 1831–1839 (2009).

  74. 74.

    Thakkar, V. et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res. Ther. 15, R193 (2013).

  75. 75.

    Hao, Y. et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res. Ther. 17, 7 (2015).

  76. 76.

    Schwaiger, J. P., Khanna, D. & Gerry Coghlan, J. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur. Respir. Rev. 22, 515–525 (2013).

  77. 77.

    Coghlan, J. G. et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann. Rheum. Dis. 73, 1340–1349 (2014).

  78. 78.

    Antoniou, K. M. et al. Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheumatol. 68, 1004–1012 (2016).

  79. 79.

    Schreiber, B. E. et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum. 63, 3531–3539 (2011).

  80. 80.

    Mihai, C. et al. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann. Rheum. Dis. 77, 128–132 (2018).

  81. 81.

    Sobanski, V. et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol. 68, 484–493 (2016).

  82. 82.

    Valerio, C. J., Schreiber, B. E., Handler, C. E., Denton, C. P. & Coghlan, J. G. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum. 65, 1074–1084 (2013).

  83. 83.

    Visovatti, S. H. et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res. Ther. 16, 493 (2014).

  84. 84.

    Bae, S. et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann. Rheum. Dis. 71, 1335–1342 (2012).

  85. 85.

    Lammi, M. R. et al. Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: observations from the PHAROS cohort. Respirology 22, 1386–1392 (2017).

  86. 86.

    Opitz, C. F. et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J. Am. Coll. Cardiol. 68, 368–378 (2016).

  87. 87.

    Chung, L. et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 146, 1494–1504 (2014).

  88. 88.

    Galiè, N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 46, 903–975 (2015).

  89. 89.

    Hager, W. D. et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. Clin. Respir. J. 7, 227–236 (2013).

  90. 90.

    Walkey, A. J., Ieong, M., Alikhan, M. & Farber, H. W. Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis. J. Rheumatol. 37, 1871–1877 (2010).

  91. 91.

    Ramjug, S. et al. Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes. Chest 152, 92–102 (2017).

  92. 92.

    Steen, V. D., Lucas, M., Fertig, N. & Medsger, T. A. Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J. Rheumatol. 34, 2230–2235 (2007).

  93. 93.

    Hinchcliff, M. et al. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry. Semin. Arthritis Rheum. 45, 309–314 (2015).

  94. 94.

    Michelfelder, M. et al. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin. Rheumatol. 36, 381–390 (2017).

  95. 95.

    Bouros, D. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 165, 1581–1586 (2002).

  96. 96.

    Wells, A. U. et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 149, 1583–1590 (1994).

  97. 97.

    Enomoto, Y. et al. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLOS One. 12, e0180283 (2017).

  98. 98.

    Hassoun, D. et al. Radiological pleuroparenchymal fibroelastosis associated to limited cutaneous systemic sclerosis: a case report. BMC Pulm. Med. 18, 73 (2018).

  99. 99.

    Pakozdi, A. et al. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J. Rheumatol. 38, 2406–2409 (2011).

  100. 100.

    Nihtyanova, S. I. & Denton, C. P. Scleroderma lung involvement, autoantibodies, and outcome prediction: the confounding effect of time. J. Rheumatol. 44, 404–406 (2017).

  101. 101.

    Nihtyanova, S. I., Parker, J. C., Black, C. M., Bunn, C. C. & Denton, C. P. A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology 48, 1218–1221 (2009).

  102. 102.

    Goh, N. S. et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248–1254 (2008).

  103. 103.

    Wallace, B. et al. Reliability, validity and responsiveness to change of the Saint George’s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology 54, 1369–1379 (2015).

  104. 104.

    Moore, O. A. et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 52, 155–160 (2013).

  105. 105.

    Tashkin, D. P. et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann. Rheum. Dis. 75, 374–381 (2016).

  106. 106.

    Volkmann, E. R. et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res. Ther. 18, 305 (2016).

  107. 107.

    Wu, W. et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-213201 (2018).

  108. 108.

    Hoffmann-Vold, A. M. et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol. 67, 2205–2212 (2015).

  109. 109.

    Khanna, D. et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res. Ther. 17, 372 (2015).

  110. 110.

    Salaffi, F. et al. Computer-aided tomographic analysis of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Correlation with pulmonary physiologic tests and patient-centred measures of perceived dyspnea and functional disability. PLOS One 11, e0149240 (2016).

  111. 111.

    van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014).

  112. 112.

    Goh, N. S. et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 69, 1670–1678 (2017).

  113. 113.

    Khanna, D. et al. The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 68, 299–311 (2016).

  114. 114.

    Moore, O. A. et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin. Exp. Rheumatol. 33 (Suppl. 91), S111–S116 (2015).

  115. 115.

    Chung, L. et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 38, 1383–1394 (2011).

  116. 116.

    Fischer, A. et al. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin. Exp. Rheumatol. 32 (Suppl. 91), S109–S114 (2014).

  117. 117.

    Barnes, H., Holland, A. E., Westall, G. P., Goh, N. S. & Glaspole, I. N. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst. Rev. 1, CD010908 (2018).

  118. 118.

    Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J.Med. 354, 2655–2666 (2006).

  119. 119.

    Tashkin, D. P. et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 176, 1026–1034 (2007).

  120. 120.

    Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962–3970 (2006).

  121. 121.

    Tashkin, D. P. et al. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of Scleroderma Lung Study II. Chest 151, 813–820 (2017).

  122. 122.

    Volkmann, E. R. et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 69, 1451–1460 (2017).

  123. 123.

    Denton, C. P. Scleroderma Lung Study II — clarity or obfuscation? Lancet Respir. Med. 4, 678–679 (2016).

  124. 124.

    Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378, 498–506 (2011).

  125. 125.

    Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018).

  126. 126.

    Saunders, P. et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials 18, 275 (2017).

  127. 127.

    Denton, C. P. et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-213031 (2018).

  128. 128.

    Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387, 2630–2640 (2016).

  129. 129.

    Betteridge, Z. E. et al. Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis. Arthritis Rheumatol. 68, 2778–2783 (2016).

  130. 130.

    Taher, T. E. et al. Defective regulation of autoreactive IL-6-producing transitional B lymphocytes is associated with disease in patients with systemic sclerosis. Arthritis Rheumatol. 70, 450–461 (2018).

  131. 131.

    Keir, G. J. et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur. Respir. J. 40, 641–648 (2012).

  132. 132.

    Rice, L. M. et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J. Clin. Invest. 125, 2795–2807 (2015).

  133. 133.

    US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02745145 (2018).

  134. 134.

    US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02921971 (2018).

  135. 135.

    Khanna, D. et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J. Rheumatol. 43, 1672–1679 (2016).

  136. 136.

    US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03221257 (2018).

  137. 137.

    Distler, O. et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin. Exp. Rheumatol. 35 (Suppl. 106), 75–81 (2017).

  138. 138.

    US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02597933 (2018).

  139. 139.

    Hsu, V. M. et al. Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase ii, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J. Rheumatol. 45, 405–410 (2017).

  140. 140.

    Black, C. M. et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 42, 299–305 (1999).

  141. 141.

    Seibold, J. R. et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 62, 2101–2108 (2010).

  142. 142.

    Volkmann, E. R., Chung, A. & Tashkin, D. P. Managing systemic sclerosis-related interstitial lung disease in the modern treatment era. J. Scleroderma Relat. Disord. 2, 72–83 (2017).

  143. 143.

    Ghataorhe, P. et al. Pulmonary arterial hypertension – progress in understanding the disease and prioritizing strategies for drug development. J. Intern. Med. 282, 129–141 (2017).

  144. 144.

    Badesch, D. B. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132, 425–434 (2000).

  145. 145.

    Badesch, D. B. et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J. Rheumatol 36, 2244–2249 (2009).

  146. 146.

    Fischer, A. et al. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a subgroup analysis of the ARIES-E clinical trial. Respir. Med. 117, 254–263 (2016).

  147. 147.

    Valerio, C. J. et al. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Rheumatology 49, 2147–2153 (2010).

  148. 148.

    Badesch, D. B. et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J. Rheumatol. 34, 2417–2422 (2007).

  149. 149.

    Denton, C. P., Humbert, M., Rubin, L. & Black, C. M. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheum. Dis. 65, 1336–1340 (2006).

  150. 150.

    Pulido, T. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 369, 809–818 (2013).

  151. 151.

    Sitbon, O. et al. Selexipag for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 373, 2522–2533 (2015).

  152. 152.

    Galiè, N. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 373, 834–844 (2015).

  153. 153.

    Hassoun, P. M. et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 192, 1102–1110 (2015).

  154. 154.

    Coghlan, J. G. et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann. Rheum. Dis. 76, 1219–1227 (2017).

  155. 155.

    Gaine, S. et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur. Respir. J. 50, 1602493 (2017).

  156. 156.

    Humbert, M. et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann. Rheum. Dis. 76, 422–426 (2017).

  157. 157.

    Sitbon, O. et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur. Respir. J. 43, 1691–1697 (2014).

  158. 158.

    Launay, D. et al. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Med. 43, e345–363 (2014).

  159. 159.

    Miele, C. H. et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann. Am. Thorac Soc. 13, 793–802 (2016).

  160. 160.

    Bernstein, E. J. et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 67, 1314–1322 (2015).

  161. 161.

    Saggar, R. et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur. Respir. J. 36, 893–900 (2010).

  162. 162.

    Khan, I. Y. et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir. Med. 107, 2081–2087 (2013).

  163. 163.

    Herrick, A. L. et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann. Rheum. Dis. 76, 1207–1218 (2017).

  164. 164.

    Domsic, R. T. et al. Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 68, 993–1003 (2016).

  165. 165.

    Domsic, R. T. et al. Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 66, 1616–1624 (2014).

  166. 166.

    Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 76, 1327–1339 (2017).

  167. 167.

    Hsu, V. M. et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin. Arthritis Rheum. 44, 55–62 (2014).

  168. 168.

    Olschewski, H. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322–329 (2002).

  169. 169.

    Oudiz, R. J. et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126, 420–427 (2004).

  170. 170.

    Barst, R. J. et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 47, 2049–2056 (2006).

  171. 171.

    McLaughlin, V. et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur. Respir. J. 46, 405–413 (2015).

Download references

Author information

Affiliations

  1. UCL Division of Medicine, Royal Free Campus, London, UK

    • Christopher P. Denton
  2. Royal Brompton Hospital, London, UK

    • Athol U. Wells
  3. Royal Free London NHS Foundation Trust, London, UK

    • John G. Coghlan

Authors

  1. Search for Christopher P. Denton in:

  2. Search for Athol U. Wells in:

  3. Search for John G. Coghlan in:

Contributions

All authors researched data for the article, provided substantial contributions to discussions of the content, wrote the article and reviewed and/or edited the article before submission.

Competing interests

C.P.D. has received honoraria from Actelion, Bayer, Boehringer Ingelheim, GlaxoSmithKline and Roche/Genentech and consultancy fees from Actelion, Bayer, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Inventiva, Merck-Serono, Roche/Genentech and Sanofi-Aventis. A.U.W. and J.G.C. declare no competing interests.

Corresponding author

Correspondence to Christopher P. Denton.

Glossary

Fibroblasts

Cells that produce extracellular matrix and that are activated inappropriately or excessively in fibrotic disease.

Myofibroblasts

Activated fibroblastic cells that have a contractile cytoskeleton that includes microfibrils containing α-smooth muscle actin.

Lung function testing

A collective term for the physiological measurement of lung volume, airways resistance and gas exchange in the lungs.

Exertional dyspnoea

Subjective breathlessness that occurs on exertion and is a cardinal feature of substantial lung complications including lung fibrosis and pulmonary hypertension.

Dyspnoea

Breathlessness that is a major symptom of lung complications in systemic sclerosis but that also has other potential causes including cardiac disease, anaemia and deconditioning.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41584-018-0062-0